Carbamazepine — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Bipolar Disorder

• Aripiprazole
• Lamotrigine
• Lithium
• Quetiapine
• Valproic Acid

Also listed for Epilepsy / Seizure Disorders

• Gabapentin
• Levetiracetam
• Phenytoin

Other medications in Neurology

• Deutetrabenazine
• Selegiline Oral
• Tetrabenazine
• Topiramate

About Carbamazepine

Carbamazepine is a vital medication used to manage various neurological conditions, from epilepsy to nerve pain. Understanding its role in your health is crucial, and with TheDrugClub, accessing this important prescription doesn't have to break the bank. We're here to help you get the care you need, often with significant savings.

Carbamazepine is a versatile medication primarily known for its anticonvulsant properties. It's widely prescribed to control and prevent seizures in individuals with epilepsy. Beyond seizure management, carbamazepine is also a cornerstone treatment for trigeminal neuralgia, a chronic pain condition affecting the trigeminal nerve, which causes severe, sudden facial pain. Furthermore, it's used as a mood stabilizer in the treatment of bipolar disorder, helping to manage manic and mixed episodes. Your doctor will determine if carbamazepine is the right choice for your specific condition based on your symptoms and medical history.

At its core, carbamazepine works by stabilizing electrical activity in the brain. It does this primarily by reducing the repetitive firing of nerve impulses. Specifically, it affects sodium channels in nerve cells, which are critical for transmitting electrical signals. By blocking these channels, carbamazepine decreases the excitability of nerve cells, thereby preventing the uncontrolled electrical discharges that lead to seizures. In trigeminal neuralgia, this same mechanism helps to quiet the overactive nerve signals responsible for the intense pain. For bipolar disorder, its mood-stabilizing effects are thought to be related to its ability to modulate neurotrans

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Carbamazepine is approved for (FDA label)

Epilepsy Carbamazepine extended-release capsules are indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvements than those with other types. Generalized tonic-clonic seizures (grand mal). Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General ). Trigeminal Neuralgia Carbamazepine extended-release capsules are indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia.

Source: Read the full FDA label on DailyMed. Label effective date: September 10, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Carbamazepine (FDA label)

WARNING SERIOUS DERMATOLOGIC REACTIONS AND HLA-B*1502 ALLELE SERIOUS AND SOMETIMES FATAL DERMATOLOGIC REACTIONS, INCLUDING TOXIC EPIDERMAL NECROLYSIS (TEN) AND STEVENS-JOHNSON SYNDROME (SJS), HAVE BEEN REPORTED DURING TREATMENT WITH CARBAMAZEPINE. THESE REACTIONS ARE ESTIMATED TO OCCUR IN 1 TO 6 PER 10,000 NEW USERS IN COUNTRIES WITH MAINLY CAUCASIAN POPULATIONS, BUT THE RISK IN SOME ASIAN COUNTRIES IS ESTIMATED TO BE ABOUT 10 TIMES HIGHER. STUDIES IN PATIENTS OF CHINESE ANCESTRY HAVE FOUND A STRONG ASSOCIATION BETWEEN THE RISK OF DEVELOPING SJS/TEN AND THE PRESENCE OF HLA-B*1502, AN INHERITED ALLELIC VARIANT OF THE HLA-B GENE. HLA-B*1502 IS FOUND ALMOST EXCLUSIVELY IN PATIENTS WITH ANCESTRY ACROSS BROAD AREAS OF ASIA. PATIENTS WITH ANCESTRY IN GENETICALLY AT-RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH CARBAMAZEPINE EXTENDED-RELEASE CAPSULES. PATIENTS TESTING POSITIVE FOR THE ALLELE SHOULD NOT BE TREATED WITH CARBAMAZEPINE EXTENDED-RELEASE CAPSULES UNLESS THE BENEFIT CLEARLY OUTWEIGHS THE RISK ( SEE WARNINGS AND PRECAUTIONS/LABORATORY TESTS ).

Source: FDA prescribing information (DailyMed). Set ID: e91f9de3-3fdd-0a6b-71ce-53a2cc142816. SPL document ID: c24e1663-4df1-d5a1-f9ed-551ba3552575. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Carbamazepine (FDA label)

General : If adverse reactions are of such severity that the drug must be discontinued, the physician must be aware that abrupt discontinuation of any anticonvulsant drug in a responsive patient with epilepsy may lead to seizures or even status epilepticus with its life-threatening hazards. The most severe adverse reactions previously observed with carbamazepine were reported in the hemopoietic system and skin (see BOXED WARNING ), and the cardiovascular system. The most frequently observed adverse reactions, particularly during the initial phases of therapy, are dizziness, drowsiness, unsteadiness, nausea, and vomiting. To minimize the possibility of such reactions, therapy should be initiated at the lowest dosage recommended.

Source: FDA prescribing information (DailyMed). Set ID: e91f9de3-3fdd-0a6b-71ce-53a2cc142816. SPL document ID: c24e1663-4df1-d5a1-f9ed-551ba3552575. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Carbamazepine (FDA label)

Carbamazepine should not be used in patients with a history of previous bone marrow depression, hypersensitivity to the drug, or known sensitivity to any of the tricyclic compounds, such as amitriptyline, desipramine, imipramine, protriptyline and nortriptyline. Likewise, on theoretical grounds its use with monoamine oxidase inhibitors is not recommended. Before administration of carbamazepine, MAO inhibitors should be discontinued for a minimum of 14 days, or longer if the clinical situation permits. Coadministration of carbamazepine and nefazodone may result in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect. Coadministration of carbamazepine with nefazodone is contraindicated. Coadministration of carbamazepine is contraindicated with delavirdine due to the potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors.

Source: FDA prescribing information (DailyMed). Set ID: e91f9de3-3fdd-0a6b-71ce-53a2cc142816. SPL document ID: c24e1663-4df1-d5a1-f9ed-551ba3552575. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Carbamazepine (FDA label)

Clinically meaningful drug interactions have occurred with concomitant medications and include, but are not limited to the following: Agents Highly Bound to Plasma Protein: Carbamazepine is not highly bound to plasma proteins; therefore, administration of carbamazepine extended-release capsules to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug. Agents that Inhibit Cytochrome P450 Isoenzymes and/or Epoxide Hydrolase: Carbamazepine is metabolized mainly by cytochrome P450 (CYP) 3A4 to the active carbamazepine 10, 11-epoxide, which is further metabolized to the trans-diol by epoxide hydrolase. Therefore, the potential exists for interaction between carbamazepine and any agent that inhibits CYP3A4 and/or epoxide hydrolase.

Source: FDA prescribing information (DailyMed). Set ID: e91f9de3-3fdd-0a6b-71ce-53a2cc142816. SPL document ID: c24e1663-4df1-d5a1-f9ed-551ba3552575. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.